The DOI matches its Crossref record.
Dopamine receptor antagonism by the novel antianxiety drug, buspirone
Open accessAbstract
Buspirone is an anxiolytic drug with a clinical potency similar to that of diazepam, but it lacks affinity for diazepam of y-aminobutyric acid (GABA) binding sites.Because previous reports suggested that buspirone may possess dopamine (DA) agonist activity, buspirone was tested for effects on DA neurotransmission.At presynaptic DA receptors, unlike other DA agonists, buspirone inhibited neither synaptosomal tyrosine hydroxylase activity nor the in vivo y-butyrolactone-induced activation of striatal tyrosine hydroxylase.However, buspirone did inhibit the action of apomorphine, a direct acting DA agonist, in both of these DA autoreceptor test systems with a potency similar to that of chlorpromazine.Striatal DA synthesis and metabolism were markedly increased by buspirone treatment; the maximum effective dose was 3.0 mg/kg, s.c., which caused a 400% increase.Extracellular single cell recordings showed that buspirone, administered intravenously, markedly increased substantia nigra DA neuronal impulse flow and potently reversed inhibition of DA cell impulse flow caused by systemic injection of apomorphine (5 to 10 pg/kg).Inhibition of DA cell impulse flow by iontophoresis of DA was reversed by iontophoretic administration of buspirone, but buspirone did not interfere with the ability of GABA to inhibit DA impulse flow.That buspirone interacts with receptor sites in addition to the DA autoreceptor was indicated by the finding that after DA receptor blockade with haloperidol, buspirone further enhanced DA neuronal impulse flow.Buspirone did not cause catalepsy and did not inhibit apomorphine-induced turning in rats with unilateral 6hydroxydopamine lesions of the substantia nigra, which indicated that the drug has minimal action at the classical postsynaptic DA receptor.These data suggest that (a) buspirone enhances DA neuronal activity, in part, by weakly inhibiting presynaptic DA receptors, and (b) buspirone has minimal effects on postsynaptic DA receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Goa, K. L., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632020-00002 · Cited by 332
Miller, J. D., Farber, J., Gatz, P., Roffwarg, H., & German, D. C. (1983) · Brain Research · doi:10.1016/0006-8993(83)91101-0 · Cited by 269
Self-citationSimić, S., Zukić, E., Schmermund, L., Faber, K., Winkler, C. K., & Kroutil, W. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00574 · Cited by 264
Buspirone: review of its pharmacology and current perspectives on its mechanism of action
Eison, A. S., & Temple, D. L. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90325-6 · Cited by 258
Davis, M., Cassella, J. V., & Kehne, J. H. (1988) · Psychopharmacology · doi:10.1007/bf00735873 · Cited by 94
Metadata
- Authors
- McMillen, B., Matthews, R., Sanghera, M., Shepard, P., & German, D.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 1983-04-01
- Volume
- 3
- Issue
- 4
- Pages
- 733-738
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1569920182
- Cited by
- 158
- References
- 0
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dopamine receptor antagonism by the novel antianxiety drug, buspirone. https://app.cochat.ai/papers/10.1523/jneurosci.03-04-00733.1983
- The paper
- McMillen, B., Matthews, R., Sanghera, M., Shepard, P., & German, D. (1983). Dopamine receptor antagonism by the novel antianxiety drug, buspirone. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.03-04-00733.1983
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.